epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Trelegy Ellipta

fluticasone furoate/ umeclidinium/ vilanterol inhaled

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  DPI: 100 mcg/62.5 mcg/25 mcg per blister, 200 mcg/62.5 mcg/25 mcg per blister

COPD, maintenance tx

[1 puff (100 mcg/62.5 mcg/25 mcg per blister) inhaled qd]
Max: 100 mcg/62.5 mcg/25 mcg/day; Info: search 'gold' for epocrates COPD GOLD decision tools

asthma, maintenance tx

[1 puff (100 mcg/62.5 mcg/25 mcg or 200 mcg/62.5 mcg/25 mcg per blister) inhaled qd]
Start: varies by disease severity and current asthma tx, may incr. dose after 2wk; Max: 200 mcg/62.5 mcg/25 mcg/day; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools

renal dosing

[see below]
renal impairment: no adjustment
HD/PD: not defined

hepatic dosing

[see below]
mild impairment: no adjustment; moderate-severe impairment: not defined, caution advised

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@21422cb1
  • hypersensitivity to drug or ingredient
  • hypersensitivity to milk protein, severe
  • status asthmaticus
  • asthma, acute
  • bronchospasm, acute
  • COPD, acute deteriorating
  • abrupt withdrawal
  • caution: hypersensitivity to corticosteroids
  • caution: MAO inhibitor use within 14 days
  • caution: TCA use within 14 days
  • caution: long-term systemic corticosteroid use, recent
  • caution: hepatic impairment, moderate-severe
  • caution: electrolyte abnormalities
  • caution: long QT syndrome, congenital
  • caution: QT prolongation
  • caution: QT prolongation family history
  • caution: torsades de pointes history
  • caution: arrhythmia
  • caution: bradycardia
  • caution: MI, recent
  • caution: CHF
  • caution: cardiovascular disease
  • caution: patients unusually responsive to sympathomimetic amines
  • caution: diabetes mellitus
  • caution: ketoacidosis
  • caution: seizure disorder
  • caution: hyperthyroidism
  • caution: labor and delivery
  • caution: immunosuppressed patients
  • caution: infection, active
  • caution: TB infection, active
  • caution: TB infection, latent
  • caution: measles exposure
  • caution: varicella exposure
  • caution: osteoporosis
  • caution: osteoporosis risk
  • caution: cataract
  • caution: glaucoma
  • caution: glaucoma risk
  • caution: glaucoma, angle-closure
  • caution: ocular HSV
  • caution: urinary retention
  • caution: prostatic hypertrophy
  • caution: bladder neck obstruction

Drug Interactions .

Overview

fluticasone furoate

corticosteroid

Interaction Characteristics:
  • CYP3A4 substrate
  • immunomodulatory effects
  • interferes w/ ACTH analog test

umeclidinium inhaled

anticholinergic inhaled

Interaction Characteristics:
  • anticholinergic effects
  • tachycardia

vilanterol inhaled

beta-2 agonist

Interaction Characteristics:
  • CYP3A4 substrate
  • hypertensive effects
  • hypokalemia
  • prolongs QT interval (conditional)
  • tachycardia

Contraindicated

  • desmopressin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    desmopressin
    2 interactions

    Contraindicated

    fluticasone furoate + desmopressin

    DESMOPRESSIN INJECTABLE: contraindicated; OTHER DESMOPRESSIN ROUTES: monitor sodium: combo may incr. risk of hyponatremia, including life-threatening (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pimozide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pimozide
    2 interactions

    Contraindicated

    vilanterol inhaled + pimozide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + pimozide

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • thioridazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    thioridazine
    2 interactions

    Contraindicated

    vilanterol inhaled + thioridazine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + thioridazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

Avoid/Use Alternative

  • acebutolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    acebutolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + acebutolol

    use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • aclidinium inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aclidinium inhaled
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + aclidinium inhaled

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • albuterol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    albuterol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + albuterol

    consider alternative if long-term use; otherwise, monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other adverse effects (additive effects, duplicate therapy)

  • amantadine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amantadine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + amantadine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • amitriptyline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amitriptyline
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + amitriptyline

    consider alternative or monitor BP, HR during and x2wk after amitriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + amitriptyline

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • amoxapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amoxapine
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + amoxapine

    consider alternative or monitor BP, HR during and x2wk after amoxapine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + amoxapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • arformoterol inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    arformoterol inhaled
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + arformoterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • arsenic trioxide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + arsenic trioxide

    use alternative or monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • atenolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atenolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + atenolol

    use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • atropine ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atropine ophthalmic
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + atropine ophthalmic

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bedaquiline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + bedaquiline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • betaxolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    betaxolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + betaxolol

    use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • bisoprolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bisoprolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + bisoprolol

    use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • botulinum toxin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    botulinum toxin
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + botulinum toxin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • carvedilol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    carvedilol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + carvedilol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • chlophedianol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlophedianol
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + chlophedianol

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • chlorcyclizine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlorcyclizine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + chlorcyclizine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • cisapride
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cisapride
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + cisapride

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + cisapride

    caution advised: combo may decr. cisapride efficacy (antagonistic effects)

  • cladribine oral
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    fluticasone furoate + cladribine oral

    use alternative: combo may incr. risk of serious infection (additive effects)

  • clomipramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clomipramine
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + clomipramine

    consider alternative or monitor BP, HR during and x2wk after clomipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Monitor/Modify Tx

    umeclidinium inhaled + clomipramine

    consider decr. dose of one or both drugs: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clozapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clozapine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + clozapine

    use alternative: combo may incr. risk of severe constipation, paralytic ileus (including life-threatening), other anticholinergic adverse effects (additive effects)

  • cocaine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cocaine
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + cocaine

    use alternative or monitor BP, HR, ECG: combo may incr. risk of severe vasoconstriction, HTN, tachycardia, arrhythmias (additive effects)

  • crizotinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + crizotinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • cyclopentolate ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cyclopentolate ophthalmic
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + cyclopentolate ophthalmic

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • darifenacin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    darifenacin
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + darifenacin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • desipramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    desipramine
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + desipramine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    vilanterol inhaled + desipramine

    consider alternative or monitor ECG, BP, HR during and x2wk after desipramine D/C: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dexbrompheniramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexbrompheniramine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + dexbrompheniramine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dexchlorpheniramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexchlorpheniramine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + dexchlorpheniramine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • domperidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    domperidone
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + domperidone

    use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + domperidone

    caution advised: combo may decr. domperidone efficacy (antagonistic effects)

  • doxepin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    doxepin
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + doxepin

    consider alternative or monitor BP, HR during and x2wk after doxepin D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + doxepin

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • doxepin topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    doxepin topical
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + doxepin topical

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dronabinol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dronabinol
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + dronabinol

    avoid combo: combo may incr. risk of tachycardia (additive effects)

    vilanterol inhaled + dronabinol

    avoid combo: combo may incr. risk of HTN, tachycardia (additive effects)

  • dronedarone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dronedarone
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + dronedarone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ephedra
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ephedra
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + ephedra

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epinephrine inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    epinephrine inhaled
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN (including hypertensive crisis), tachycardia, other cardiovascular adverse effects (additive effects)

  • esmolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    esmolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + esmolol

    use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • fesoterodine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fesoterodine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + fesoterodine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • fexinidazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + fexinidazole

    if possible, do not initiate fexinidazole until 5 half-lives after vilanterol inhaled D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flavoxate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    flavoxate
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + flavoxate

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • fluphenazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fluphenazine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + fluphenazine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • formoterol inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    formoterol inhaled
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + formoterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • fosfomycin injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fosfomycin injection
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + fosfomycin injection

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • furosemide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + furosemide

    use alternative or monitor BP, potassium: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • glucagon
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    glucagon
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + glucagon

    avoid combo if glucagon used as radiologic diagnostic aid: combo may incr. risk of severe constipation, paralytic ileus, other GI adverse effects (additive effects)

  • glycopyrronium topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    glycopyrronium topical
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + glycopyrronium topical

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • hydroxychloroquine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydroxychloroquine
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + hydroxychloroquine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • hydroxyzine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydroxyzine
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + hydroxyzine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + hydroxyzine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • hyoscyamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hyoscyamine
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + hyoscyamine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + hyoscyamine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • imipramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    imipramine
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + imipramine

    consider alternative or monitor BP, HR during and x2wk after imipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + imipramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • ipratropium nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ipratropium nasal
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + ipratropium nasal

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • labetalol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    labetalol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + labetalol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • landiolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    landiolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + landiolol

    use alternative or monitor HR, BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • lefamulin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + lefamulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lonafarnib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lonafarnib
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + lonafarnib

    use alternative or monitor BP, HR, ECG, electrolytes: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + lonafarnib

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • metoprolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    metoprolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + metoprolol

    use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • midodrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    midodrine
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + midodrine

    use alternative or monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • mobocertinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + mobocertinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • molindone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    molindone
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + molindone

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • nadolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nadolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + nadolol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • natalizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    natalizumab
    1 interaction

    Avoid/Use Alternative

    fluticasone furoate + natalizumab

    avoid combo: combo may incr. risk of serious infection (additive effects)

  • nebivolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nebivolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + nebivolol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • nortriptyline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nortriptyline
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + nortriptyline

    consider alternative or monitor BP, HR during and x2wk after nortriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + nortriptyline

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • olanzapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    olanzapine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + olanzapine

    avoid combo: combo may incr. risk of life-threatening anticholinergic adverse effects, including constipation, paralytic ileus, hyperthermia (additive effects)

  • olodaterol inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    olodaterol inhaled
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + olodaterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • orphenadrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    orphenadrine
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + orphenadrine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + orphenadrine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • oxybutynin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oxybutynin
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + oxybutynin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • phenelzine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenelzine
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + phenelzine

    consider alternative or monitor BP, HR during and x2wk after phenelzine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + phenelzine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • pimecrolimus topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pimecrolimus topical
    1 interaction

    Avoid/Use Alternative

    fluticasone furoate + pimecrolimus topical

    avoid combo: combo may incr. risk of serious infection (additive effects)

  • pindolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pindolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + pindolol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • procarbazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    procarbazine
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + procarbazine

    use alternative or monitor BP, HR during and x2wk after procarbazine D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

    Caution Advised

    fluticasone furoate + procarbazine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • propranolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    propranolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + propranolol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • protriptyline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    protriptyline
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + protriptyline

    consider alternative or monitor BP, HR during and x2wk after protriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + protriptyline

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pyrilamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pyrilamine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + pyrilamine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • quinidine (antiarrhythmic)
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    quinidine (antiarrhythmic)
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + quinidine (antiarrhythmic)

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + quinidine (antiarrhythmic)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    quinidine (CYP2D6 inhibitor)
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + quinidine (CYP2D6 inhibitor)

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quizartinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    quizartinib
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + quizartinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    fluticasone furoate + quizartinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • revefenacin inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    revefenacin inhaled
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + revefenacin inhaled

    avoid combo: combo may incr. anticholinergic adverse effects (additive effects)

  • rivastigmine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rivastigmine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + rivastigmine

    use alternative: combo may decrease efficacy of both drugs (antagonistic effects)

  • salmeterol inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    salmeterol inhaled
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + salmeterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • scopolamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    scopolamine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + scopolamine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • sofpironium topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sofpironium topical
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + sofpironium topical

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • solifenacin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    solifenacin
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + solifenacin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • sotalol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sotalol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + sotalol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. efficacy of both drugs (additive effects; antagonistic effects)

  • thiothixene
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    thiothixene
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + thiothixene

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • timolol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    timolol
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + timolol

    use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • tolterodine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tolterodine
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + tolterodine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • toremifene
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + toremifene

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trihexyphenidyl
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trihexyphenidyl
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + trihexyphenidyl

    avoid combo: combo may incr. risk of hyperthermia, anticholinergic adverse effects (additive effects)

  • trimipramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trimipramine
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + trimipramine

    consider alternative or monitor BP, HR during and x2wk after nortriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + trimipramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • tropicamide ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tropicamide ophthalmic
    1 interaction

    Avoid/Use Alternative

    umeclidinium inhaled + tropicamide ophthalmic

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • trospium
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trospium
    2 interactions

    Avoid/Use Alternative

    umeclidinium inhaled + trospium

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    vilanterol inhaled + trospium

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • vandetanib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    vilanterol inhaled + vandetanib

    use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • ziprasidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ziprasidone
    2 interactions

    Avoid/Use Alternative

    vilanterol inhaled + ziprasidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + ziprasidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

Monitor/Modify Tx

  • abiraterone acetate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + abiraterone acetate

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • acetazolamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    acetazolamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + acetazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • adagrasib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    adagrasib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + adagrasib

    monitor ECG, BP, HR: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + adagrasib

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • albuterol inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + albuterol inhaled

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • aliskiren
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • almotriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aloe
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + aloe

    monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

  • amiloride
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • aminophylline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + aminophylline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • amiodarone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + amiodarone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • amlodipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amphetamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + amphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • amphotericin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + amphotericin

    monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

  • anagrelide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    anagrelide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + anagrelide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • angiotensin II
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

  • apalutamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    apalutamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + apalutamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • apomorphine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + apomorphine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • aprocitentan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • armodafinil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    armodafinil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + armodafinil

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • artemether/lumefantrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + artemether/ lumefantrine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asciminib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asenapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    asenapine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + asenapine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + asenapine

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • asparaginase
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + asparaginase

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • atazanavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atazanavir
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + atazanavir

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + atazanavir

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • atogepant
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atomoxetine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + atomoxetine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • atropine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atropine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + atropine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    umeclidinium inhaled + atropine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • axitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • azilsartan medoxomil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • azithromycin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    azithromycin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + azithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • benazepril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benzphetamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + benzphetamine

    monitor BP, HR: combo may incr. risk of tachycardia, HTN, other cardiovascular adverse effects (additive effects)

  • benztropine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    benztropine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + benztropine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    umeclidinium inhaled + benztropine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • betamethasone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    betamethasone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + betamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + betamethasone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bevacizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bismuth subsalicylate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • brigatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + brigatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • budesonide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    budesonide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + budesonide

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + budesonide

    caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • bumetanide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + bumetanide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • bupropion
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + bupropion

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • cabozantinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + cabozantinib

    monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • caffeine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + caffeine

    monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects)

  • caffeine citrate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + caffeine citrate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • candesartan cilexetil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cannabis
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cannabis
    2 interactions

    Monitor/Modify Tx

    umeclidinium inhaled + cannabis

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    vilanterol inhaled + cannabis

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • captopril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carfilzomib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    carfilzomib
    2 interactions

    Monitor/Modify Tx

    fluticasone furoate + carfilzomib

    consider antiviral prophylaxis: combo may incr. risk of serious infection (additive effects)

    vilanterol inhaled + carfilzomib

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • celecoxib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ceritinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ceritinib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ceritinib

    monitor ECG, electrolytes, BP, HR: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + ceritinib

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • cetuximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cetuximab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + cetuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chloramphenicol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chloramphenicol
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + chloramphenicol

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + chloramphenicol

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • chloroquine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chloroquine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + chloroquine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • chlorothiazide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + chlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • chlorthalidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + chlorthalidone

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • cisplatin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cisplatin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + cisplatin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + cisplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • citalopram
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + citalopram

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clarithromycin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clarithromycin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + clarithromycin

    monitor ECG, BP, HR: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + clarithromycin

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • clevidipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clofazimine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + clofazimine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clonidine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cobicistat
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cobicistat
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + cobicistat

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + cobicistat

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • copanlisib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    copanlisib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

    Caution Advised

    fluticasone furoate + copanlisib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • corticotropin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    corticotropin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + corticotropin

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + corticotropin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cortisone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cortisone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + cortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + cortisone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cosyntropin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cosyntropin
    1 interaction

    Monitor/Modify Tx

    fluticasone furoate + cosyntropin

    hold fluticasone on day of test: combo may interfere with test results (fluticasone may alter plasma cortisol levels)

  • cyclosporine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cyclosporine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + cyclosporine

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + cyclosporine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • danazol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • darbepoetin alfa
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • decitabine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    decitabine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + decitabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deflazacort
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    deflazacort
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + deflazacort

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + deflazacort

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • degarelix
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    degarelix
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + degarelix

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + desflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desvenlafaxine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + desvenlafaxine

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • dexamethasone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexamethasone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + dexamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + dexamethasone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • dexmedetomidine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dexmedetomidine

    monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dexmedetomidine injection

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmethylphenidate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dexmethylphenidate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dextroamphetamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dextroamphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dichlorphenamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dichlorphenamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dichlorphenamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • diclofenac
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dicyclomine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dicyclomine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + dicyclomine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    umeclidinium inhaled + dicyclomine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • diethylpropion
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + diethylpropion

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • diflunisal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • digoxin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + digoxin

    monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

  • dihydroergotamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dihydroergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • diltiazem
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dinutuximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dinutuximab
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + dinutuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + dinutuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • disopyramide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    disopyramide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + disopyramide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + disopyramide

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dobutamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dobutamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dobutamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dofetilide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dofetilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • donepezil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    donepezil
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + donepezil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + donepezil

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • dopamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dopamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dopamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dordaviprone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dordaviprone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + dordaviprone

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • doxapram
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + doxapram

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • doxazosin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • droperidol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    droperidol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + droperidol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • droxidopa
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

  • eletriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • emapalumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    emapalumab
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + emapalumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + emapalumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • enalapril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • encorafenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    encorafenib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + encorafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ephedrine injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ephedrine injection

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • ephedrine oral
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ephedrine oral

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epinephrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + epinephrine

    monitor potassium, ECG, BP, HR: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epirubicin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    epirubicin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + epirubicin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    fluticasone furoate + epirubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • eplerenone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + eplerenone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epoetin alfa
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eptinezumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    eptinezumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • erenumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    erenumab
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    umeclidinium inhaled + erenumab

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • ergotamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • eribulin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    eribulin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + eribulin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    fluticasone furoate + eribulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • erythromycin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    erythromycin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + erythromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + erythromycin

    caution advised: combo may decr. erythromycin efficacy when used for GI promotility (antagonistic effects)

  • esketamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + esketamine

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • estetrol (contraceptive)
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • estradiol (contraceptive)
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ethacrynic acid
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ethacrynic acid

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • ethanol (alcoholic beverage)
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • ethinyl estradiol (contraceptive)
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etodolac
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etrasimod
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    etrasimod
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + etrasimod

    caution advised during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • everolimus
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    fluticasone furoate + everolimus

    admin. PCP prophylaxis: combo may incr. risk of serious infection (additive effects)

  • felodipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + felodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenfluramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenoldopam
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fingolimod
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fingolimod
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + fingolimod

    caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • flecainide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + flecainide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fludrocortisone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fludrocortisone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + fludrocortisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + fludrocortisone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fluorouracil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fluorouracil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flurbiprofen
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • foscarnet
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + foscarnet

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • fosinopril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fostamatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fremanezumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fremanezumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • frovatriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fruquintinib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    Caution Advised

    fluticasone furoate + fruquintinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • galcanezumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    galcanezumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • gilteritinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + gilteritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • glasdegib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    glasdegib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + glasdegib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • glycopyrrolate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    glycopyrrolate
    2 interactions

    Monitor/Modify Tx

    umeclidinium inhaled + glycopyrrolate

    monitor HR: combo may incr. risk of tachycardia, anticholinergic adverse effects (additive effects)

    vilanterol inhaled + glycopyrrolate

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • goserelin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    goserelin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + goserelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • guanfacine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • haloperidol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + haloperidol

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    histrelin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + histrelin

    consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hoodia
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + hoodia

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • hydralazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + hydrochlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • hydrocortisone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydrocortisone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + hydrocortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + hydrocortisone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • hydroxocobalamin IV
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibrutinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ibrutinib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ibrutinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + ibrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ibuprofen
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibutilide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ibutilide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ibutilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • idelalisib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    idelalisib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + idelalisib

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + idelalisib

    caution advised: combo may incr. plasma fluticasone exposure, risk of serious infection, systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited, additive effects)

  • indapamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + indapamide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • indomethacin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • inotuzumab ozogamicin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    inotuzumab ozogamicin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + inotuzumab ozogamicin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    fluticasone furoate + inotuzumab ozogamicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • insulin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + insulin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • irbesartan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • isocarboxazid
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    isocarboxazid
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + isocarboxazid

    monitor BP, HR during and x2wk after isocarboxazid D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + isocarboxazid

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • isoflurane
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + isoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoproterenol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    isoproterenol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + isoproterenol

    monitor potassium, HR: combo may incr. risk of hypokalemia, tachycardia (additive effects)

  • isradipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • itraconazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    itraconazole
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + itraconazole

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + itraconazole

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • ivosidenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ivosidenib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ivosidenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ketamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ketamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other sympathomimetic adverse effects (additive effects)

  • ketoconazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ketoconazole
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ketoconazole

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + ketoconazole

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • ketoprofen
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketorolac
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lanreotide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leflunomide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    leflunomide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + leflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + leflunomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lenalidomide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lenalidomide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + lenalidomide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + lenalidomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lenvatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leuprolide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    leuprolide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + leuprolide

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levalbuterol inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + levalbuterol inhaled

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • levofloxacin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    levofloxacin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + levofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levoketoconazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    levoketoconazole
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + levoketoconazole

    monitor ECG, BP, HR: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + levoketoconazole

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • levomilnacipran
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + levomilnacipran

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • levothyroxine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + levothyroxine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • licorice
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + licorice

    monitor BP, potassium w/ large amounts of licorice: combo may incr. risk of HTN, hypokalemia (additive effects)

  • lifileucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lifileucel

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • linezolid
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + linezolid

    monitor BP, HR during and x2wk after linezolid D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • liothyronine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + liothyronine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • liraglutide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    liraglutide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + liraglutide

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • lisdexamfetamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lisdexamfetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • lisinopril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lofexidine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lofexidine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lofexidine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lopinavir/ritonavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lopinavir/ ritonavir
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + lopinavir/ ritonavir

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + lopinavir/ ritonavir

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • lorlatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lorlatinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lorlatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • losartan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lumacaftor/ivacaftor
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + lumacaftor/ ivacaftor

    monitor BP: combo may incr. risk of HTN (additive effects)

  • luspatercept
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • macimorelin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    macimorelin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + macimorelin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium citrate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + magnesium citrate

    monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium salicylate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • mannitol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + mannitol

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • meclofenamate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mefenamic acid
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

  • meloxicam
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methacholine inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methacholine inhaled
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + methacholine inhaled

    hold vilanterol at least 36h before methacholine test: combo may interfere with test results (antagonistic effects)

    Caution Advised

    fluticasone furoate + methacholine inhaled

    caution advised: combo may interfere with test results (antagonistic effects)

  • methadone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methadone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • methamphetamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methamphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • methazolamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methazolamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methscopolamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methscopolamine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + methscopolamine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    umeclidinium inhaled + methscopolamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • methyldopa
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methylergonovine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • methylphenidate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methylphenidate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • methylprednisolone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methylprednisolone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + methylprednisolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + methylprednisolone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • methyltestosterone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metoclopramide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    metoclopramide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    umeclidinium inhaled + metoclopramide

    caution advised: combo may decr. metoclopramide efficacy (antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying)

  • metolazone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + metolazone

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • metyrapone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    metyrapone
    1 interaction

    Monitor/Modify Tx

    fluticasone furoate + metyrapone

    D/C fluticasone 5 half-lives before metyrapone test: combo may alter test results (antagonistic effects, exogenous corticosteroids may interfere with test)

  • mifepristone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mifepristone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + mifepristone

    monitor BP, HR, potassium during and x14 days after daily mifepristone use: combo may incr. vilanterol exposure, risk of HTN, tachycardia, hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + mifepristone

    caution advised w/in 14 days of daily mifepristone use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • milnacipran
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + milnacipran

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • minoxidil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mirabegron
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + mirabegron

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + mirabegron

    caution advised: combo may incr. risk of urinary retention (additive effects)

  • mitomycin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    fluticasone furoate + mitomycin

    caution advised; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of serious infection (additive effects)

  • modafinil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    modafinil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + modafinil

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • moexipril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • motixafortide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    motixafortide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + motixafortide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • moxifloxacin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    moxifloxacin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + moxifloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • nabumetone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naproxen
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naratriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naxitamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • necitumumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + necitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • nefazodone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nefazodone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + nefazodone

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + nefazodone

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • nelfinavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nelfinavir
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + nelfinavir

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + nelfinavir

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • nicardipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nifedipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + nifedipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nilotinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + nilotinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • nimodipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + nimodipine

    monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

  • niraparib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + nisoldipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • norepinephrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + norepinephrine

    monitor BP, HR: combo may incr. risk of severe HTN, other cardiovascular adverse effects (additive effects)

  • obinutuzumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    obinutuzumab
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    Caution Advised

    fluticasone furoate + obinutuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • oliceridine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + oliceridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • olmesartan medoxomil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ondansetron
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ondansetron
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ondansetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • osilodrostat
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + osilodrostat

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • osimertinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    osimertinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + osimertinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxaprozin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxymetazoline nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + oxymetazoline nasal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • oxytocin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ozanimod
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ozanimod

    monitor BP, HR during and x2wk after ozanimod D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    fluticasone furoate + ozanimod

    caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • pacritinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pacritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • paliperidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    paliperidone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + paliperidone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + paliperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • palonosetron
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    palonosetron
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + palonosetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pamidronate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pamidronate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • panitumumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    panitumumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + panitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pasireotide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pasireotide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pasireotide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pazopanib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pentamidine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pentamidine

    monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • perindopril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pexidartinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pexidartinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pexidartinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phendimetrazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phendimetrazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenoxybenzamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phentermine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phentolamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phenylephrine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenylephrine injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phenylephrine injection

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • phenylephrine nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phenylephrine nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenylephrine ophthalmic
    2 interactions

    Monitor/Modify Tx

    umeclidinium inhaled + phenylephrine ophthalmic

    monitor HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of tachycardia (additive effects)

    vilanterol inhaled + phenylephrine ophthalmic

    monitor BP, HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN, tachycardia (additive effects)

  • phenylephrine rectal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + phenylephrine rectal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • piroxicam
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • polyethylene glycol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + polyethylene glycol

    monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • polyethylene glycol/electrolytes
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + polyethylene glycol/ electrolytes

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • ponatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ponatinib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + ponatinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ponesimod
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ponesimod
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + ponesimod

    caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • posaconazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    posaconazole
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + posaconazole

    monitor BP, HR, potassium: combo may incr. vilanterol exposure, risk of HTN, tachycardia, hypokalemia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + posaconazole

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • pralsetinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pralsetinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pralsetinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • prazosin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    prednisolone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + prednisolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + prednisolone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • prednisone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    prednisone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + prednisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + prednisone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • procainamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    procainamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + procainamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • propafenone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + propafenone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pseudoephedrine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + pseudoephedrine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • quetiapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    quetiapine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

    Caution Advised

    umeclidinium inhaled + quetiapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • quinapril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • quinine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + quinine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ramipril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rasagiline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + rasagiline

    monitor BP, HR during and x2wk after rasagiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • regorafenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    regorafenib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + regorafenib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • revumenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    revumenib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + revumenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribociclib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ribociclib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ribociclib

    monitor ECG, electrolytes, BP, HR: combo may incr. vilanterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    Caution Advised

    fluticasone furoate + ribociclib

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • rimegepant
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ripretinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ritonavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ritonavir
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + ritonavir

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + ritonavir

    caution advised; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • rizatriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • romidepsin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    romidepsin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + romidepsin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    fluticasone furoate + romidepsin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ropinirole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ropinirole

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rotigotine transdermal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + rotigotine transdermal

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • rucaparib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rucaparib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + rucaparib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sacituzumab govitecan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sacituzumab govitecan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sacituzumab govitecan

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • safinamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    safinamide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + safinamide

    monitor BP, HR during and x2wk after safinamide D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • salsalate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + salsalate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • selegiline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    selegiline
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + selegiline

    monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • selegiline transdermal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    selegiline transdermal
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + selegiline transdermal

    monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • selinexor
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    selinexor
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + selinexor

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + selinexor

    caution advised: combo may incr. risk of serious infection (additive effects)

  • selpercatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + selpercatinib

    monitor ECG, BP, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • sevoflurane
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sevoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • siponimod
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    siponimod
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + siponimod

    caution advised during and x3-4wk after siponimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • sirolimus albumin-bound
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sirolimus albumin-bound
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + sirolimus albumin-bound

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + sirolimus albumin-bound

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sodium benzoate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sodium benzoate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sodium benzoate

    monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylacetate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sodium phenylacetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylbutyrate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sodium phenylbutyrate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium polystyrene sulfonate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sodium polystyrene sulfonate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sodium polystyrene sulfonate

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sodium thiosulfate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sodium thiosulfate
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sodium thiosulfate

    if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

  • solriamfetol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    solriamfetol
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + solriamfetol

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • sorafenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • spironolactone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sulfate bowel prep
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sulfate bowel prep

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sulindac
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sumatriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tacrolimus
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tacrolimus
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + tacrolimus

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + tacrolimus

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tafasitamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tafasitamab
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + tafasitamab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + tafasitamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tagraxofusp
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • taletrectinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    taletrectinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + taletrectinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telavancin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + telavancin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telmisartan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terazosin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + terbutaline

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • teriflunomide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    teriflunomide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + teriflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + teriflunomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • testosterone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tetrabenazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tetrabenazine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + tetrabenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • theophylline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + theophylline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • thyroid
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + thyroid

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • tipranavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tipranavir
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + tipranavir

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + tipranavir

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • tivozanib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • tolmetin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • topiramate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    topiramate
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + topiramate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    umeclidinium inhaled + topiramate

    caution advised, especially in Peds pts: combo may incr. risk of hyperthermia (additive effects)

  • torsemide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + torsemide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • tramadol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tramadol
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + tramadol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    umeclidinium inhaled + tramadol

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • trametinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • trandolapril
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tranylcypromine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tranylcypromine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + tranylcypromine

    monitor BP, HR during and x2wk after tranylcypromine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    umeclidinium inhaled + tranylcypromine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • triamcinolone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    triamcinolone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + triamcinolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    fluticasone furoate + triamcinolone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • triamterene
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triclabendazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    triclabendazole
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + triclabendazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trifluridine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trifluridine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + trifluridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • triptorelin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    triptorelin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + triptorelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • tucatinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tucatinib
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + tucatinib

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + tucatinib

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • ubrogepant
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ubrogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vadadustat
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + vadadustat

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • valsartan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vamorolone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vamorolone
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + vamorolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    fluticasone furoate + vamorolone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vasopressin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vemurafenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vemurafenib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + vemurafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • venlafaxine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • verapamil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + verapamil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • viloxazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    viloxazine
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + viloxazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    fluticasone furoate + viloxazine

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • voclosporin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    voclosporin
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    fluticasone furoate + voclosporin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • voriconazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    voriconazole
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + voriconazole

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

    Caution Advised

    fluticasone furoate + voriconazole

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • yohimbe
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + yohimbe

    monitor BP, HR during and x2wk after yohimbe D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • zavegepant
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    zavegepant
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ziftomenib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ziftomenib
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ziftomenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ziv-aflibercept
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zolmitriptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    vilanterol inhaled + zolmitriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zonisamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    zonisamide
    2 interactions

    Monitor/Modify Tx

    vilanterol inhaled + zonisamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    umeclidinium inhaled + zonisamide

    caution advised, especially in Peds pts: combo may incr. risk of hyperthermia (additive effects)

Caution Advised

  • abatacept
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    abatacept
    1 interaction

    Caution Advised

    fluticasone furoate + abatacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • abemaciclib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    abemaciclib
    1 interaction

    Caution Advised

    fluticasone furoate + abemaciclib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • abrocitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    abrocitinib
    1 interaction

    Caution Advised

    fluticasone furoate + abrocitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • acalabrutinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    acalabrutinib
    1 interaction

    Caution Advised

    fluticasone furoate + acalabrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • aceclidine ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aceclidine ophthalmic
    1 interaction

    Caution Advised

    umeclidinium inhaled + aceclidine ophthalmic

    caution advised: combo may decr. aceclidine efficacy (antagonistic effects)

  • adalimumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    adalimumab
    1 interaction

    Caution Advised

    fluticasone furoate + adalimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • afamitresgene autoleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    afamitresgene autoleucel
    1 interaction

    Caution Advised

    fluticasone furoate + afamitresgene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • aldesleukin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aldesleukin
    1 interaction

    Caution Advised

    fluticasone furoate + aldesleukin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • alemtuzumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    alemtuzumab
    1 interaction

    Caution Advised

    fluticasone furoate + alemtuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • alfentanil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    alfentanil
    1 interaction

    Caution Advised

    umeclidinium inhaled + alfentanil

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • alosetron
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    alosetron
    1 interaction

    Caution Advised

    umeclidinium inhaled + alosetron

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • anakinra
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    anakinra
    1 interaction

    Caution Advised

    fluticasone furoate + anakinra

    caution advised: combo may incr. risk of serious infection (additive effects)

  • anifrolumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    anifrolumab
    1 interaction

    Caution Advised

    fluticasone furoate + anifrolumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • anti-thymocyte globulin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    anti-thymocyte globulin
    1 interaction

    Caution Advised

    fluticasone furoate + anti-thymocyte globulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • aripiprazole bimonthly injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aripiprazole bimonthly injection
    1 interaction

    Caution Advised

    umeclidinium inhaled + aripiprazole bimonthly injection

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • aripiprazole lauroxil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aripiprazole lauroxil
    1 interaction

    Caution Advised

    umeclidinium inhaled + aripiprazole lauroxil

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • aripiprazole monthly injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aripiprazole monthly injection
    1 interaction

    Caution Advised

    umeclidinium inhaled + aripiprazole monthly injection

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • aripiprazole oral
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    aripiprazole oral
    1 interaction

    Caution Advised

    umeclidinium inhaled + aripiprazole oral

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • atidarsagene autotemcel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    atidarsagene autotemcel
    1 interaction

    Caution Advised

    fluticasone furoate + atidarsagene autotemcel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • avacopan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    avacopan
    1 interaction

    Caution Advised

    fluticasone furoate + avacopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • axicabtagene ciloleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    axicabtagene ciloleucel
    1 interaction

    Caution Advised

    fluticasone furoate + axicabtagene ciloleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • azacitidine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    azacitidine
    1 interaction

    Caution Advised

    fluticasone furoate + azacitidine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • azathioprine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    azathioprine
    1 interaction

    Caution Advised

    fluticasone furoate + azathioprine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • baricitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    baricitinib
    1 interaction

    Caution Advised

    fluticasone furoate + baricitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • basiliximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    basiliximab
    1 interaction

    Caution Advised

    fluticasone furoate + basiliximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • beclomethasone inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    beclomethasone inhaled
    1 interaction

    Caution Advised

    fluticasone furoate + beclomethasone inhaled

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • beclomethasone nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    beclomethasone nasal
    1 interaction

    Caution Advised

    fluticasone furoate + beclomethasone nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • belatacept
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    belatacept
    1 interaction

    Caution Advised

    fluticasone furoate + belatacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belimumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    belimumab
    1 interaction

    Caution Advised

    fluticasone furoate + belimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belinostat
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    belinostat
    1 interaction

    Caution Advised

    fluticasone furoate + belinostat

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belladonna alkaloids
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    belladonna alkaloids
    1 interaction

    Caution Advised

    umeclidinium inhaled + belladonna alkaloids

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • bendamustine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bendamustine
    1 interaction

    Caution Advised

    fluticasone furoate + bendamustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bethanechol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bethanechol
    1 interaction

    Caution Advised

    umeclidinium inhaled + bethanechol

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • bimekizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bimekizumab
    1 interaction

    Caution Advised

    fluticasone furoate + bimekizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • blinatumomab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    blinatumomab
    1 interaction

    Caution Advised

    fluticasone furoate + blinatumomab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bortezomib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    bortezomib
    1 interaction

    Caution Advised

    fluticasone furoate + bortezomib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brentuximab vedotin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    brentuximab vedotin
    1 interaction

    Caution Advised

    fluticasone furoate + brentuximab vedotin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brexpiprazole
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    brexpiprazole
    1 interaction

    Caution Advised

    umeclidinium inhaled + brexpiprazole

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • brexucabtagene autoleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    brexucabtagene autoleucel
    1 interaction

    Caution Advised

    fluticasone furoate + brexucabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brodalumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    brodalumab
    1 interaction

    Caution Advised

    fluticasone furoate + brodalumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brompheniramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    brompheniramine
    1 interaction

    Caution Advised

    umeclidinium inhaled + brompheniramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • budesonide inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    budesonide inhaled
    1 interaction

    Caution Advised

    fluticasone furoate + budesonide inhaled

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • budesonide nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    budesonide nasal
    1 interaction

    Caution Advised

    fluticasone furoate + budesonide nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • budesonide rectal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    budesonide rectal
    1 interaction

    Caution Advised

    fluticasone furoate + budesonide rectal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • buprenorphine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    buprenorphine
    1 interaction

    Caution Advised

    umeclidinium inhaled + buprenorphine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • busulfan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    busulfan
    1 interaction

    Caution Advised

    fluticasone furoate + busulfan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cabazitaxel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cabazitaxel
    1 interaction

    Caution Advised

    fluticasone furoate + cabazitaxel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • canakinumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    canakinumab
    1 interaction

    Caution Advised

    fluticasone furoate + canakinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • carbinoxamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    carbinoxamine
    1 interaction

    Caution Advised

    umeclidinium inhaled + carbinoxamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • carboplatin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    carboplatin
    1 interaction

    Caution Advised

    fluticasone furoate + carboplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cariprazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cariprazine
    1 interaction

    Caution Advised

    umeclidinium inhaled + cariprazine

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • carmustine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    carmustine
    1 interaction

    Caution Advised

    fluticasone furoate + carmustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • certolizumab pegol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    certolizumab pegol
    1 interaction

    Caution Advised

    fluticasone furoate + certolizumab pegol

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cevimeline
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cevimeline
    1 interaction

    Caution Advised

    umeclidinium inhaled + cevimeline

    caution advised: combo may decrease efficacy of both drugs (antagonistic effects)

  • chlorambucil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlorambucil
    1 interaction

    Caution Advised

    fluticasone furoate + chlorambucil

    caution advised: combo may incr. risk of serious infection (additive effects)

  • chlorpheniramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlorpheniramine
    1 interaction

    Caution Advised

    umeclidinium inhaled + chlorpheniramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • chlorpromazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    chlorpromazine
    1 interaction

    Caution Advised

    umeclidinium inhaled + chlorpromazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • ciltacabtagene autoleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ciltacabtagene autoleucel
    1 interaction

    Caution Advised

    fluticasone furoate + ciltacabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cladribine injection
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cladribine injection
    1 interaction

    Caution Advised

    fluticasone furoate + cladribine injection

    caution advised: combo may incr. risk of serious infection (additive effects)

  • clemastine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clemastine
    1 interaction

    Caution Advised

    umeclidinium inhaled + clemastine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clidinium
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clidinium
    1 interaction

    Caution Advised

    umeclidinium inhaled + clidinium

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clobetasol ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clobetasol ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + clobetasol ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • clofarabine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    clofarabine
    1 interaction

    Caution Advised

    fluticasone furoate + clofarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • conivaptan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    conivaptan
    1 interaction

    Caution Advised

    fluticasone furoate + conivaptan

    caution advised during and x7 days after conivaptan tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited)

  • crovalimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    crovalimab
    1 interaction

    Caution Advised

    fluticasone furoate + crovalimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cyclobenzaprine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cyclobenzaprine
    1 interaction

    Caution Advised

    umeclidinium inhaled + cyclobenzaprine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • cyclophosphamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cyclophosphamide
    1 interaction

    Caution Advised

    fluticasone furoate + cyclophosphamide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cyproheptadine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cyproheptadine
    1 interaction

    Caution Advised

    umeclidinium inhaled + cyproheptadine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • cytarabine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    cytarabine
    1 interaction

    Caution Advised

    fluticasone furoate + cytarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dactinomycin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dactinomycin
    1 interaction

    Caution Advised

    fluticasone furoate + dactinomycin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • danicopan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    danicopan
    1 interaction

    Caution Advised

    fluticasone furoate + danicopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • daratumumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    daratumumab
    1 interaction

    Caution Advised

    fluticasone furoate + daratumumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • darunavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    darunavir
    1 interaction

    Caution Advised

    fluticasone furoate + darunavir

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • daunorubicin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    daunorubicin
    1 interaction

    Caution Advised

    fluticasone furoate + daunorubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • delgocitinib topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    delgocitinib topical
    1 interaction

    Caution Advised

    fluticasone furoate + delgocitinib topical

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deucravacitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    deucravacitinib
    1 interaction

    Caution Advised

    fluticasone furoate + deucravacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deuruxolitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    deuruxolitinib
    1 interaction

    Caution Advised

    fluticasone furoate + deuruxolitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dexamethasone ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dexamethasone ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + dexamethasone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • difenoxin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    difenoxin
    1 interaction

    Caution Advised

    umeclidinium inhaled + difenoxin

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • difluprednate ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    difluprednate ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + difluprednate ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • dihydrocodeine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dihydrocodeine
    1 interaction

    Caution Advised

    umeclidinium inhaled + dihydrocodeine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • dimenhydrinate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dimenhydrinate
    1 interaction

    Caution Advised

    umeclidinium inhaled + dimenhydrinate

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dimethyl fumarate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dimethyl fumarate
    1 interaction

    Caution Advised

    fluticasone furoate + dimethyl fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • diphenhydramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diphenhydramine
    1 interaction

    Caution Advised

    umeclidinium inhaled + diphenhydramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • diroximel fumarate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    diroximel fumarate
    1 interaction

    Caution Advised

    fluticasone furoate + diroximel fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • docetaxel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    docetaxel
    1 interaction

    Caution Advised

    fluticasone furoate + docetaxel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • doxorubicin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    doxorubicin
    1 interaction

    Caution Advised

    fluticasone furoate + doxorubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • doxylamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    doxylamine
    1 interaction

    Caution Advised

    umeclidinium inhaled + doxylamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dupilumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    dupilumab
    1 interaction

    Caution Advised

    fluticasone furoate + dupilumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • duvelisib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    duvelisib
    1 interaction

    Caution Advised

    fluticasone furoate + duvelisib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • eculizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    eculizumab
    1 interaction

    Caution Advised

    fluticasone furoate + eculizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • efgartigimod alfa
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    efgartigimod alfa
    1 interaction

    Caution Advised

    fluticasone furoate + efgartigimod alfa

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elivaldogene autotemcel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    elivaldogene autotemcel
    1 interaction

    Caution Advised

    fluticasone furoate + elivaldogene autotemcel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elotuzumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    elotuzumab
    1 interaction

    Caution Advised

    fluticasone furoate + elotuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elranatamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    elranatamab
    1 interaction

    Caution Advised

    fluticasone furoate + elranatamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • epcoritamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    epcoritamab
    1 interaction

    Caution Advised

    fluticasone furoate + epcoritamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • etanercept
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    etanercept
    1 interaction

    Caution Advised

    fluticasone furoate + etanercept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • etoposide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    etoposide
    1 interaction

    Caution Advised

    fluticasone furoate + etoposide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • etuvetidigene autotemcel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    etuvetidigene autotemcel
    1 interaction

    Caution Advised

    fluticasone furoate + etuvetidigene autotemcel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • floxuridine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    floxuridine
    1 interaction

    Caution Advised

    fluticasone furoate + floxuridine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fludarabine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fludarabine
    1 interaction

    Caution Advised

    fluticasone furoate + fludarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • flunisolide nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    flunisolide nasal
    1 interaction

    Caution Advised

    fluticasone furoate + flunisolide nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluocinolone intravitreal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fluocinolone intravitreal
    1 interaction

    Caution Advised

    fluticasone furoate + fluocinolone intravitreal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluorometholone ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fluorometholone ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + fluorometholone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluticasone propionate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fluticasone propionate
    1 interaction

    Caution Advised

    fluticasone furoate + fluticasone propionate

    caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fosamprenavir
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    fosamprenavir
    1 interaction

    Caution Advised

    fluticasone furoate + fosamprenavir

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • galantamine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    galantamine
    1 interaction

    Caution Advised

    umeclidinium inhaled + galantamine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • gemtuzumab ozogamicin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    gemtuzumab ozogamicin
    1 interaction

    Caution Advised

    fluticasone furoate + gemtuzumab ozogamicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • gepotidacin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    gepotidacin
    1 interaction

    Caution Advised

    umeclidinium inhaled + gepotidacin

    caution advised: combo may decr. umeclidinium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

  • glofitamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    glofitamab
    1 interaction

    Caution Advised

    fluticasone furoate + glofitamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • glycopyrrolate inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    glycopyrrolate inhaled
    1 interaction

    Caution Advised

    umeclidinium inhaled + glycopyrrolate inhaled

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • golimumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    golimumab
    1 interaction

    Caution Advised

    fluticasone furoate + golimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • guselkumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    guselkumab
    1 interaction

    Caution Advised

    fluticasone furoate + guselkumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • homatropine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    homatropine
    1 interaction

    Caution Advised

    umeclidinium inhaled + homatropine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • hydrocortisone ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydrocortisone ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + hydrocortisone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • hydroxyurea
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    hydroxyurea
    1 interaction

    Caution Advised

    fluticasone furoate + hydroxyurea

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ibritumomab tiuxetan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ibritumomab tiuxetan
    1 interaction

    Caution Advised

    fluticasone furoate + ibritumomab tiuxetan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • icotrokinra
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    icotrokinra
    1 interaction

    Caution Advised

    fluticasone furoate + icotrokinra

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idarubicin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    idarubicin
    1 interaction

    Caution Advised

    fluticasone furoate + idarubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idecabtagene vicleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    idecabtagene vicleucel
    1 interaction

    Caution Advised

    fluticasone furoate + idecabtagene vicleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ifosfamide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ifosfamide
    1 interaction

    Caution Advised

    fluticasone furoate + ifosfamide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • iloperidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    iloperidone
    1 interaction

    Caution Advised

    umeclidinium inhaled + iloperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • inebilizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    inebilizumab
    1 interaction

    Caution Advised

    fluticasone furoate + inebilizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • infliximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    infliximab
    1 interaction

    Caution Advised

    fluticasone furoate + infliximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ipratropium inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ipratropium inhaled
    1 interaction

    Caution Advised

    umeclidinium inhaled + ipratropium inhaled

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • iptacopan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    iptacopan
    1 interaction

    Caution Advised

    fluticasone furoate + iptacopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • irinotecan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    irinotecan
    1 interaction

    Caution Advised

    fluticasone furoate + irinotecan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • isatuximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    isatuximab
    1 interaction

    Caution Advised

    fluticasone furoate + isatuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ixabepilone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ixabepilone
    1 interaction

    Caution Advised

    fluticasone furoate + ixabepilone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ixekizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ixekizumab
    1 interaction

    Caution Advised

    fluticasone furoate + ixekizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lebrikizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lebrikizumab
    1 interaction

    Caution Advised

    fluticasone furoate + lebrikizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • levorphanol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    levorphanol
    1 interaction

    Caution Advised

    umeclidinium inhaled + levorphanol

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • linvoseltamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    linvoseltamab
    1 interaction

    Caution Advised

    fluticasone furoate + linvoseltamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lisocabtagene maraleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lisocabtagene maraleucel
    1 interaction

    Caution Advised

    fluticasone furoate + lisocabtagene maraleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lomustine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lomustine
    1 interaction

    Caution Advised

    fluticasone furoate + lomustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • loncastuximab tesirine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    loncastuximab tesirine
    1 interaction

    Caution Advised

    fluticasone furoate + loncastuximab tesirine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • loteprednol ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    loteprednol ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + loteprednol ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • loxapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    loxapine
    1 interaction

    Caution Advised

    umeclidinium inhaled + loxapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • lumateperone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lumateperone
    1 interaction

    Caution Advised

    umeclidinium inhaled + lumateperone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • lurasidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lurasidone
    1 interaction

    Caution Advised

    umeclidinium inhaled + lurasidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Caution Advised

    fluticasone furoate + lymphocyte immune globulin, anti-thymocyte globulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • meclizine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    meclizine
    1 interaction

    Caution Advised

    umeclidinium inhaled + meclizine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • melphalan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    melphalan
    1 interaction

    Caution Advised

    fluticasone furoate + melphalan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mercaptopurine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mercaptopurine
    1 interaction

    Caution Advised

    fluticasone furoate + mercaptopurine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • methotrexate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    methotrexate
    1 interaction

    Caution Advised

    fluticasone furoate + methotrexate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • milsaperidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    milsaperidone
    1 interaction

    Caution Advised

    umeclidinium inhaled + milsaperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • mirikizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mirikizumab
    1 interaction

    Caution Advised

    fluticasone furoate + mirikizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mirtazapine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mirtazapine
    1 interaction

    Caution Advised

    umeclidinium inhaled + mirtazapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • mitoxantrone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mitoxantrone
    1 interaction

    Caution Advised

    fluticasone furoate + mitoxantrone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mogamulizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mogamulizumab
    1 interaction

    Caution Advised

    fluticasone furoate + mogamulizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • momelotinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    momelotinib
    1 interaction

    Caution Advised

    fluticasone furoate + momelotinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mometasone implant
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mometasone implant
    1 interaction

    Caution Advised

    fluticasone furoate + mometasone implant

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mometasone inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mometasone inhaled
    1 interaction

    Caution Advised

    fluticasone furoate + mometasone inhaled

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • mometasone nasal
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mometasone nasal
    1 interaction

    Caution Advised

    fluticasone furoate + mometasone nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • monomethyl fumarate
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    monomethyl fumarate
    1 interaction

    Caution Advised

    fluticasone furoate + monomethyl fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mosunetuzumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mosunetuzumab
    1 interaction

    Caution Advised

    fluticasone furoate + mosunetuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mycophenolate mofetil
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mycophenolate mofetil
    1 interaction

    Caution Advised

    fluticasone furoate + mycophenolate mofetil

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mycophenolic acid
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    mycophenolic acid
    1 interaction

    Caution Advised

    fluticasone furoate + mycophenolic acid

    caution advised: combo may incr. risk of serious infection (additive effects)

  • narsoplimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    narsoplimab
    1 interaction

    Caution Advised

    fluticasone furoate + narsoplimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • nelarabine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nelarabine
    1 interaction

    Caution Advised

    fluticasone furoate + nelarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • neostigmine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    neostigmine
    1 interaction

    Caution Advised

    umeclidinium inhaled + neostigmine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • nipocalimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    nipocalimab
    1 interaction

    Caution Advised

    fluticasone furoate + nipocalimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • obecabtagene autoleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    obecabtagene autoleucel
    1 interaction

    Caution Advised

    fluticasone furoate + obecabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ocrelizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ocrelizumab
    1 interaction

    Caution Advised

    fluticasone furoate + ocrelizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ofatumumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ofatumumab
    1 interaction

    Caution Advised

    fluticasone furoate + ofatumumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • oxaliplatin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oxaliplatin
    1 interaction

    Caution Advised

    fluticasone furoate + oxaliplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • oxymorphone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    oxymorphone
    1 interaction

    Caution Advised

    umeclidinium inhaled + oxymorphone

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • paclitaxel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    paclitaxel
    1 interaction

    Caution Advised

    fluticasone furoate + paclitaxel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pegcetacoplan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pegcetacoplan
    1 interaction

    Caution Advised

    fluticasone furoate + pegcetacoplan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pentostatin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pentostatin
    1 interaction

    Caution Advised

    fluticasone furoate + pentostatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • peppermint
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    peppermint
    1 interaction

    Caution Advised

    fluticasone furoate + peppermint

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • perphenazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    perphenazine
    1 interaction

    Caution Advised

    umeclidinium inhaled + perphenazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pheniramine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pheniramine
    1 interaction

    Caution Advised

    umeclidinium inhaled + pheniramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pilocarpine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pilocarpine
    1 interaction

    Caution Advised

    umeclidinium inhaled + pilocarpine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • pilocarpine ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pilocarpine ophthalmic
    1 interaction

    Caution Advised

    umeclidinium inhaled + pilocarpine ophthalmic

    caution advised: combo may decr. pilocarpine efficacy (antagonistic effects)

  • pirtobrutinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pirtobrutinib
    1 interaction

    Caution Advised

    fluticasone furoate + pirtobrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • polatuzumab vedotin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    polatuzumab vedotin
    1 interaction

    Caution Advised

    fluticasone furoate + polatuzumab vedotin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pomalidomide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pomalidomide
    1 interaction

    Caution Advised

    fluticasone furoate + pomalidomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pozelimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pozelimab
    1 interaction

    Caution Advised

    fluticasone furoate + pozelimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pramlintide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pramlintide
    1 interaction

    Caution Advised

    umeclidinium inhaled + pramlintide

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • prednisolone ophthalmic
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    prednisolone ophthalmic
    1 interaction

    Caution Advised

    fluticasone furoate + prednisolone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • prochlorperazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    prochlorperazine
    1 interaction

    Caution Advised

    umeclidinium inhaled + prochlorperazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • promethazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    promethazine
    1 interaction

    Caution Advised

    umeclidinium inhaled + promethazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pyridostigmine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    pyridostigmine
    1 interaction

    Caution Advised

    umeclidinium inhaled + pyridostigmine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • ravulizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ravulizumab
    1 interaction

    Caution Advised

    fluticasone furoate + ravulizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rilonacept
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rilonacept
    1 interaction

    Caution Advised

    fluticasone furoate + rilonacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rilzabrutinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rilzabrutinib
    1 interaction

    Caution Advised

    fluticasone furoate + rilzabrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • risankizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    risankizumab
    1 interaction

    Caution Advised

    fluticasone furoate + risankizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • risperidone
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    risperidone
    1 interaction

    Caution Advised

    umeclidinium inhaled + risperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • ritlecitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ritlecitinib
    1 interaction

    Caution Advised

    fluticasone furoate + ritlecitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rituximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rituximab
    1 interaction

    Caution Advised

    fluticasone furoate + rituximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ropeginterferon alfa-2b
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ropeginterferon alfa-2b
    1 interaction

    Caution Advised

    fluticasone furoate + ropeginterferon alfa-2b

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rozanolixizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    rozanolixizumab
    1 interaction

    Caution Advised

    fluticasone furoate + rozanolixizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ruxolitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ruxolitinib
    1 interaction

    Caution Advised

    fluticasone furoate + ruxolitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ruxolitinib topical
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ruxolitinib topical
    1 interaction

    Caution Advised

    fluticasone furoate + ruxolitinib topical

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sarilumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sarilumab
    1 interaction

    Caution Advised

    fluticasone furoate + sarilumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • satralizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    satralizumab
    1 interaction

    Caution Advised

    fluticasone furoate + satralizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • secukinumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    secukinumab
    1 interaction

    Caution Advised

    fluticasone furoate + secukinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sibeprenlimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sibeprenlimab
    1 interaction

    Caution Advised

    fluticasone furoate + sibeprenlimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • siltuximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    siltuximab
    1 interaction

    Caution Advised

    fluticasone furoate + siltuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sirolimus
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sirolimus
    1 interaction

    Caution Advised

    fluticasone furoate + sirolimus

    caution advised: combo may incr. risk of serious infection (additive effects)

  • spesolimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    spesolimab
    1 interaction

    Caution Advised

    fluticasone furoate + spesolimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sulfasalazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sulfasalazine
    1 interaction

    Caution Advised

    fluticasone furoate + sulfasalazine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sutimlimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    sutimlimab
    1 interaction

    Caution Advised

    fluticasone furoate + sutimlimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • talquetamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    talquetamab
    1 interaction

    Caution Advised

    fluticasone furoate + talquetamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tapentadol
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tapentadol
    1 interaction

    Caution Advised

    umeclidinium inhaled + tapentadol

    caution advised: combo may increase risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • tarlatamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tarlatamab
    1 interaction

    Caution Advised

    fluticasone furoate + tarlatamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • teclistamab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    teclistamab
    1 interaction

    Caution Advised

    fluticasone furoate + teclistamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • temozolomide
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    temozolomide
    1 interaction

    Caution Advised

    fluticasone furoate + temozolomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • temsirolimus
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    temsirolimus
    1 interaction

    Caution Advised

    fluticasone furoate + temsirolimus

    caution advised: combo may incr. risk of serious infection (additive effects)

  • teplizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    teplizumab
    1 interaction

    Caution Advised

    fluticasone furoate + teplizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • thioguanine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    thioguanine
    1 interaction

    Caution Advised

    fluticasone furoate + thioguanine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • thiotepa
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    thiotepa
    1 interaction

    Caution Advised

    fluticasone furoate + thiotepa

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tildrakizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tildrakizumab
    1 interaction

    Caution Advised

    fluticasone furoate + tildrakizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tiotropium inhaled
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tiotropium inhaled
    1 interaction

    Caution Advised

    umeclidinium inhaled + tiotropium inhaled

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • tisagenlecleucel
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tisagenlecleucel
    1 interaction

    Caution Advised

    fluticasone furoate + tisagenlecleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tocilizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tocilizumab
    1 interaction

    Caution Advised

    fluticasone furoate + tocilizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tofacitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tofacitinib
    1 interaction

    Caution Advised

    fluticasone furoate + tofacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • topotecan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    topotecan
    1 interaction

    Caution Advised

    fluticasone furoate + topotecan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • trabectedin
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trabectedin
    1 interaction

    Caution Advised

    fluticasone furoate + trabectedin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tralokinumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    tralokinumab
    1 interaction

    Caution Advised

    fluticasone furoate + tralokinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • trifluoperazine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    trifluoperazine
    1 interaction

    Caution Advised

    umeclidinium inhaled + trifluoperazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • triprolidine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    triprolidine
    1 interaction

    Caution Advised

    umeclidinium inhaled + triprolidine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • ublituximab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ublituximab
    1 interaction

    Caution Advised

    fluticasone furoate + ublituximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • upadacitinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    upadacitinib
    1 interaction

    Caution Advised

    fluticasone furoate + upadacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ustekinumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    ustekinumab
    1 interaction

    Caution Advised

    fluticasone furoate + ustekinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vedolizumab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vedolizumab
    1 interaction

    Caution Advised

    fluticasone furoate + vedolizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • venetoclax
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    venetoclax
    1 interaction

    Caution Advised

    fluticasone furoate + venetoclax

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vibegron
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vibegron
    1 interaction

    Caution Advised

    umeclidinium inhaled + vibegron

    caution advised: combo may incr. risk of urinary retention (additive effects)

  • vilobelimab
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vilobelimab
    1 interaction

    Caution Advised

    fluticasone furoate + vilobelimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vinblastine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vinblastine
    1 interaction

    Caution Advised

    fluticasone furoate + vinblastine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vincristine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vincristine
    1 interaction

    Caution Advised

    fluticasone furoate + vincristine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vinorelbine
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    vinorelbine
    1 interaction

    Caution Advised

    fluticasone furoate + vinorelbine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • zanubrutinib
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    zanubrutinib
    1 interaction

    Caution Advised

    fluticasone furoate + zanubrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • zilucoplan
  • Trelegy Ellipta (fluticasone furoate/ umeclidinium/ vilanterol inhaled)
    +
    zilucoplan
    1 interaction

    Caution Advised

    fluticasone furoate + zilucoplan

    caution advised: combo may incr. risk of serious infection (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@7d6b1e53
  • bronchospasm, paradoxical
  • asthma exacerbation
  • pneumonia (COPD use)
  • hypersensitivity reaction
  • anaphylaxis
  • angioedema
  • HTN
  • angina
  • arrhythmia
  • hypokalemia
  • hyperglycemia
  • Churg-Strauss syndrome
  • fractures
  • adrenal suppression (long-term use)
  • hypercorticism (long-term use)
  • immunosuppression (long-term use)
  • glaucoma (long-term use)
  • cataracts (long-term use)
  • osteoporosis (long-term use)

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@98cc6c2
  • URI symptoms
  • headache
  • back pain
  • dysgeusia
  • diarrhea
  • UTI
  • candidiasis, oral

Safety/Monitoring .

Monitoring Parameters
BMD at baseline if osteoporosis risk factors or COPD, then periodically; oral cavity exam periodically; consider ophthalmic exam if long-term use, change in vision, IOP/glaucoma/cataracts history

Pregnancy/Lactation .

Pregnancy

Clinical Summary

fluticasone furoate: may use during pregnancy; risk of teratogenicity low based on human data

umeclidinium inhaled: weigh risk/benefit during pregnancy; no human data available; no known risk of teratogenicity based on animal data at 40x and 150x MRHD

vilanterol inhaled: weigh risk/benefit during pregnancy, especially during labor and delivery; no human data available; no known risk of teratogenicity based on animal data at up to 120x MRHD; risk of interference with uterine contractility based on drug's mechanism of action

Lactation

Clinical Summary

fluticasone furoate: may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal systemic absorption in breastfeeding patients and drug properties; no human data available to assess effects on milk production

umeclidinium inhaled: may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal systemic absorption in breastfeeding patients and drug properties; no human data available to assess effects on milk production

vilanterol inhaled: may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal systemic absorption in breastfeeding patients and drug properties; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@39a8845b

Metabolism: for fluticasone: liver primarily; CYP450: 3A4 substrate; Info: minimal systemic absorption; for umeclidinium: liver primarily; CYP450: 2D6 substrate; Info: minimal systemic absorption; for vilanterol: liver primarily; CYP450: 3A4 substrate; Info: minimal systemic absorption

Excretion: for fluticasone: feces 90-101%, urine 1-2%; Half-life: 24h; for umeclidinium: feces 58-92%, urine <23%; Half-life: 11h; for vilanterol: urine 70%, feces 30%; Half-life: 11h

Subclass: Beta-2 Agonists, Inhaled Long-Acting (LABAs) ; Corticosteroids, Inhaled ; Muscarinic Antagonists, Inhaled Long-Acting (LAMAs)

Mechanism of Action
for fluticasone: exact mechanism of anti-inflammatory action unknown; inhibits multiple inflammatory cytokines; produces multiple glucocorticoid and mineralocorticoid effects; for umeclidinium: antagonizes acetylcholine receptors, producing bronchodilation; for vilanterol: selectively stimulates beta-2 adrenergic receptors, relaxing airway smooth muscle

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: GlaxoSmithKline

com.epocrates.rxweb.beans.DrugOtherInfoBean@7ca0512f

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

inhalation powder:

  • 100 mcg/62.5 mcg/25 mcg (1 inhaler, 60 blisters): $624.00
  • 200 mcg/62.5 mcg/25 mcg (1 inhaler, 60 blisters): $624.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information